TNXP
NASDAQ
US
Tonix Pharmaceuticals Holding Corp. - Common Stock
$13.90
▲ +$0.22
(+1.61%)
Vol 314K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$199.7M
ROE
-55.2%
Margin
-963.4%
D/E
0.00
Beta
1.93
52W
$7–$70
Wall Street Consensus
8 analysts · Apr 20262
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
SABS
SAB Biotherapeutics Inc
P/E 9.5
$178.0M
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
MGNX
MacroGenics Inc
$101.8M
CRBU
Caribou Biosciences Inc
$148.6M
CRBP
Corbus Pharmaceuticals Holdings Inc
$142.9M
GALT
Galectin Therapeutics Inc
$268.2M
ACHV
Achieve Life Sciences Inc
$264.6M
SGMT
Sagimet Biosciences Inc
$183.5M
Earnings
Beat rate: 50.0%
Next Report
May 11, 2026
EPS Estimate: $-2.82
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-2.82 | — | — |
| Dec 2025 | $-3.25 | $-3.98 | $-0.73 |
| Sep 2025 | $-3.66 | $-3.59 | +$0.07 |
| Jun 2025 | $-3.28 | $-3.86 | $-0.58 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -57.9% | -57.9% | -57.9% | -57.9% | -55.2% | -55.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -1415.0% | -828.2% | -828.2% | -828.2% | -963.4% | -963.4% |
| Gross Margin | -63.8% | 29.3% | 29.3% | 29.3% | 34.3% | 34.3% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 7.53 | 7.53 | 7.53 | 7.53 | 9.89 | 9.89 |
Key Ratios
ROA (TTM)
-49.9%
P/S (TTM)
19.40
P/B
0.4
EPS (TTM)
$-20.11
CF/Share
$-10.41
52W High
$69.97
52W Low
$6.76
$6.76
52-Week Range
$69.97
How does TNXP compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
TNXP valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
19.4
▲
51%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.4
▼
82%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
TNXP profitability vs Biotechnology peers
ROE
-55.2%
▲
18%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-963.4%
▼
236%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
34.3%
▼
56%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-49.9%
▼
7%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
TNXP financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
9.9
▲
123%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.9
▲
99%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
TNXP fundamentals radar
TNXP
Peer median
Industry
TNXP profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
TNXP vs peers: key metrics
Latest News
No related news yet